Endothelium

EyeCare Partners’ Leadership and Clinical Research to be Showcased at American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Thursday, May 4, 2023
Surgery, Health, Science, Research, Optical, Dark, Partner, Eye drop, Ophthalmology, ASCRS, Varenicline, Telecanthus, Patient satisfaction, Ciclosporin, Patient experience, ECP, Presbyopia, Ageing, Randomness, Cataract, Legacy Devers Eye Institute, Wonderful, Manual, Refractive surgery, Endothelium, Ocular hypertension, American Society of Cataract and Refractive Surgery, Somatosensory system, Ketamine, Contact lens, Political moderate, Learning curve, Pilocarpine, DED, Retina, Midazolam, Phacoemulsification, Corneal neovascularization, Loteprednol, Immunosuppression, Physician, Pivotal, Society, Treatment, Rejuvenation, Veterinary medicine, Nursing, Hospital, Telescopic sight, Medical imaging, Pharmaceutical industry, Casino, PRK, Tacrolimus, LASIK, Creatinine, History, Patient

The annual meeting will take place May 5-8, 2023, in San Diego.

Key Points: 
  • The annual meeting will take place May 5-8, 2023, in San Diego.
  • The breadth of topics being presented at ASCRS by ECP physicians emphasizes the company’s culture of innovation and continuous learning.
  • It also underscores the possibility of a career “third pathway” which allows physicians to conduct industry-leading research while also continuing to build a clinical practice.
  • “EyeCare Partners has a strong representation of ophthalmologists presenting research at ASCRS this year, in addition to one of our specialists, Dr. Elizabeth Yeu, serving as the incoming president of ASCRS,” said David Clark, CEO of EyeCare Partners.

Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Tuesday, May 2, 2023
Health, General Health, Research, Science, Optical, Biotechnology, American Society of Cataract and Refractive Surgery, Cataract, Refractive surgery, ASCRS, Patient, Society, Endothelium, Ophthalmology, Annual general meeting, Medical imaging, Pharmaceutical industry

Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held May 5-8, 2023 in San Diego, California.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held May 5-8, 2023 in San Diego, California.
  • At Eyecelerator and ASCRS 2023 , data will be presented from the Company’s Escalón study, which treated subjects with its novel cell therapy, AURN001.
  • “We are thrilled to share Escalón findings in multiple sessions at the ASCRS 2023 and Eyecelerator meetings,” said Michael Goldstein, president and chief medical officer, Aurion Biotech.
  • “Escalón data are consistent with our previous trials showing clinically meaningful improvements in central corneal thickness and best corrected visual acuity.

New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgery

Retrieved on: 
Monday, April 24, 2023
Health, Clinical Trials, General Health, Pharmaceutical, Optical, Biotechnology, ARVO, Descemet's membrane, Cornea, Cataract, Endothelium, DSO, Gene expression, Tert-Butyl hydroperoxide, Oxidative stress, Patient, Annual general meeting, Association for Research in Vision and Ophthalmology, Research, FGF, Therapy, Visual acuity, Safety, Wound healing, Pharmaceutical industry, Medical imaging, Health insurance, Fuchs, Ophthalmology

Across all patients, TTHX1114 produced a dose-dependent response in resolution of corneal edema and improvement of best corrected visual acuity (BCVA) following surgery.

Key Points: 
  • Across all patients, TTHX1114 produced a dose-dependent response in resolution of corneal edema and improvement of best corrected visual acuity (BCVA) following surgery.
  • The proportion of patients with complete resolution of corneal edema in the high-dose groups at 28 days after surgery was similar in patients with DSO vs. those with DSO and cataract surgery (25.9% vs 17.4%).
  • It is exciting to see TTHX1114 perform well in controlling post-surgical edema in at-risk patients undergoing cataract surgery,” said Eveleth.
  • However, visual outcomes for patients undergoing DSO did not appear to be adversely affected by concurrent cataract surgery.

Trefoil Therapeutics Announces TTHX1114 Data Presentations at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting

Retrieved on: 
Monday, April 17, 2023
Health, Health Technology, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Fuchs, ARVO, Cornea, Lycée Français de la Nouvelle-Orléans, Research, DSO, Patient, Role, Therapy, Endothelium, Fibroblast growth factor, Medical imaging, Ophthalmology

Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans, April 23-27, 2023.

Key Points: 
  • Trefoil Therapeutics , a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans, April 23-27, 2023.
  • “We aim to address an unmet clinical need with TTHX1114 by offering the potential to restore vision by stimulating and protecting the cornea’s own endothelial cells,” said David Eveleth, Ph.D., President and CEO of Trefoil Therapeutics.
  • His topic will be: The Role of Fibroblast Growth Factor derivatives in corneal endothelial regeneration which will be presented from 9:13-9:27 am.
  • Trefoil will also be present at booth #1156.

World Precision Instruments Introduces EVOM™ Auto, combining Transepithelial Electrical Resistance (TEER) Measurements with a High Throughput Format for Drug Discovery

Retrieved on: 
Thursday, April 13, 2023
Tissue, Drug development, Gastrointestinal tract, Traffic barrier, HTS, Cell, Lung, WPI, Drug combination, Drug discovery, Health, Endothelium, Skin, Software, Medical device

SARASOTA, Fla., April 13, 2023 /PRNewswire/ -- World Precision Instruments (WPI) is excited to launch the newest member to its EVOM™ family of products, the EVOM™ Auto.

Key Points: 
  • SARASOTA, Fla., April 13, 2023 /PRNewswire/ -- World Precision Instruments (WPI) is excited to launch the newest member to its EVOM™ family of products, the EVOM™ Auto.
  • The new EVOM™ Auto enables rapid and reproducible measurements of Transepithelial Electrical Resistance (TEER), a well-established and widely accepted method of evaluating epithelial and endothelial cells and tissues, in vitro.
  • WPI's EVOM™ Auto combines TEER technology with high throughput screening capabilities, resulting in the automated measurement of resistance in 96-well cell culture plates.
  • "The need for fast and precise readouts of in vitro assays for drug development is at an all-time high.

Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Health, Pharmaceutical, Surgery, Professional Services, Optical, Stem Cells, University, Research, Education, Start-Up, Hospitals, Science, Clinical Trials, Fujita Health University, Cornea, Human, Inc., Society, Safety, Efficacy, Visual impairment, Cataract, Keio University, Paratriathlon, Medicine, Regenerative medicine, Eye, Patient, Water, FIH, Corneal transplantation, Transplant, Visual acuity, IPS, Study, Conference, Endothelium, Disease, Pharmaceutical industry, Dentistry, Ophthalmology

Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference (Kyoto, Japan, March 23-25, 2023) that iPS cell-derived corneal endothelial cell substitute ("CLS001") was transplanted to the first patient (First In Human*, "FIH Study").

Key Points: 
  • Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference (Kyoto, Japan, March 23-25, 2023) that iPS cell-derived corneal endothelial cell substitute ("CLS001") was transplanted to the first patient (First In Human*, "FIH Study").
  • In addition, in terms of the efficacy, he also reported that the visual acuity, central corneal thickness, and minimal corneal thickness has tended to be improved so far.
  • Currently, the only treatment available for this disease is a corneal transplant that replaces normally functioning corneal endothelial cells.
  • Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied to more than half of all cases of corneal transplantation.

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

Retrieved on: 
Thursday, March 23, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Infection, PK, Cornea, ECD, Kyoto Prefectural University of Medicine, Medicines and Healthcare products Regulatory Agency, Gene editing, Eye, CCT, Cell, Doctor of Philosophy, Regenerative medicine, Dislocation, Astigmatism, Patient, PMDA, Ageing, Visual acuity, OUS, Endothelium, Disease, Pharmaceutical industry, Medical imaging, EU, MD

The Company believes this is the first-ever regulatory approval in the world for an allogeneic cell therapy to treat corneal endothelial disease.

Key Points: 
  • The Company believes this is the first-ever regulatory approval in the world for an allogeneic cell therapy to treat corneal endothelial disease.
  • “The approval of Vyznova™ in Japan represents many firsts – for millions of patients in need, for regenerative medicine and for Aurion Biotech, including the first-ever approval of a cell therapy to treat corneal endothelial disease,” said Greg Kunst, chief executive officer, Aurion Biotech.
  • Without gene editing, fully differentiated CECs from a single donor can be produced to treat more than 100 recipient eyes.
  • “PMDA approval is an essential step in bringing this cell therapy to patients in need in Japan.

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Retrieved on: 
Wednesday, February 15, 2023
Choroid, CNV, LTB4, Vance DeGeneres, Eye, Engineering, Drug discovery, Professor, ARVO, Intravitreal injection, Anxiety, VEGF, VEGF-A, C5, E pluribus unum, Tufts University School of Medicine, Leukotriene B4, Depression, Food, Risk, Choroidal neovascularization, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Endothelium, GMP, Leukotriene, Hot game, Geographic atrophy, American Society for Clinical Investigation, Blood, Therapy, Andrew Conway Ivy, Patient, Incidence, Retina, IVT, Visual system, AAO, Intellectual property, Kinetics, AMD, Inflammation, Medscape, PAS, PEGylation, Injection, McClard, Infection, IND, Pharmaceutical industry, Vaccine, Ophthalmology, Medicare, Akari

PASylation (PAS) technology is a biological alternative to the chemical conjugate polyethylene glycol (PEGylation) in the development of extended half-life recombinant protein therapeutics.

Key Points: 
  • PASylation (PAS) technology is a biological alternative to the chemical conjugate polyethylene glycol (PEGylation) in the development of extended half-life recombinant protein therapeutics.
  • Complement overactivation is a validated target and an important aspect in the pathophysiology of GA, while LTB4 may contribute to overexpression of VEGF-A, a key driver of CNV.
  • “Patients who have geographic atrophy also are at risk of developing an additional sight-threatening condition known as choroidal neovascularization or CNV, which presents more hurdles in the fight to preserve sight.
  • Medscape article on 24-month data presentation at AAO 2022 With Approval Pending, Pegcetacoplan Shows Mixed Results for Treating Geographic Atrophy https://www.medscape.com/viewarticle/981813#vp_2
    McClard CK, et al.

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure

Retrieved on: 
Monday, January 30, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, NOX2, Lipid, Cell, Oxidative stress, AMF, INSIGHT, Phase, Metabolomics, Radical, DSM-IV codes, American Heart Association, European Society of Cardiology, Executive Committee, Risk, Volunteering, Blood pressure, PEA, Human, Blood, Fibrinogen, BPI, Endothelium, NAFL, European Regional Development Fund, ERDF, White, Serum, Cardiovascular disease, Research and development, AHA, Development, Translational research, Metabolism, Inflammation, MCP-1, ESC, Discovery, Hypertension, Popular Executive Committee of Valencia, Disease, European, Pharmaceutical industry, Dietary supplement, Europe 1

Damage to the vascular wall is a major mechanism in the progression of high blood pressure.

Key Points: 
  • Damage to the vascular wall is a major mechanism in the progression of high blood pressure.
  • This first-in-human evidence confirms the relevance of TOTUM•854's positioning in the early stages of the disease and bodes well for the ongoing Phase II/III clinical efficacy studies in high blood pressure."
  • Mode of action tests also revealed a reduction in angiotensin I-converting enzyme (ACE1) activity, an enzyme well known in the pathophysiology of high blood pressure.
  • 3The fraction of blood remaining after all blood cells (red blood cells, leukocytes, platelets) and fibrinogen (a protein involved in coagulation) have been removed.

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

Retrieved on: 
Friday, February 10, 2023
Safety, VEGF, Bevacizumab, Endothelium, The Group, Eye, IgG4-related ophthalmic disease, Patient, Clinical trial, Union, KDR, Ranibizumab, Research, Week, Pharmaceutical industry, EU

Previously, the first patients in the European Union (EU) and Australia were dosed in the same global multicenter phase 3 clinical trial of EB12-20145P (HLX04-O).

Key Points: 
  • Previously, the first patients in the European Union (EU) and Australia were dosed in the same global multicenter phase 3 clinical trial of EB12-20145P (HLX04-O).
  • Meanwhile, the first patient has been dosed in a parallel phase 3 clinical trial in China for EB12-20145P (HLX04-O) for the treatment of wAMD.
  • This randomised, double-blinded, active-controlled, global phase 3 study aims to compare the efficacy and safety of EB12-20145P (HLX04-O) with ranibizumab in patients with wet age-related macular degeneration (wAMD).
  • EB12-20145P (HLX04-O) has the potential to be one of the first bevacizumab approved for use in ophthalmic diseases, benefiting more patients with eye diseases worldwide.